Astrazeneca

Astrazeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

About Astrazeneca

Latest Astrazeneca Share price

LON: AZN Dividends

Historical Data

Latest Astrazeneca News

AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York,...
AstraZeneca

AstraZeneca signs $1.2bn obesity drug collaboration with CSPC

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four...
AstraZeneca

AstraZeneca to move Nasdaq listing to NYSE

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq...
AstraZeneca

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for...
intravenous (IV) line

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric...
AstraZeneca

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in...
AstraZeneca

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and...
AstraZeneca

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for...
AstraZeneca

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic...
AstraZeneca

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for...
AstraZeneca

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus...
intravenous (IV) line

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal...

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.